Clot-busting treatment for late-window posterior stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether a clot-busting drug called pro-urokinase can help people with a stroke in the back of the brain when given later than usual (4.5 to 9 hours after symptoms start). The goal is to see if it improves recovery and reduces disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your stroke symptoms started 4.5 to 9 hours before you would start the study medicine (including strokes noticed upon waking).
- An MRI shows the stroke is recent and the damaged area is not too large.
- You have a moderate to moderately severe stroke (score 4–25 on a stroke severity scale).
- You have not had a major stroke or disability before this one, and you can care for yourself.
- You are not expected to have a procedure to remove the clot (thrombectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This study tests a clot-busting medicine given through an IV to people who had a stroke caused by a blocked medium-sized blood vessel in the brain, and who can be treated 4.5 to 24 hours after symptoms start. The goal is to see if it improves recovery and reduces disability compared to standard care.
This study tests a clot-dissolving medication given within 4.5 hours of a stroke caused by a blocked blood vessel. The goal is to see how well it works in real-world patients and to help improve recovery.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.